Restart Life Sciences Corp.
NMLSF
$0.06
$0.0111.07%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -198.58% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -198.58% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -198.58% |
| SG&A Expenses | 130.58% | 87.15% | 37.44% | -45.98% | -59.99% |
| Depreciation & Amortization | -23.53% | -22.22% | -21.05% | -20.00% | -22.73% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 130.24% | 87.06% | 31.29% | -49.08% | -61.95% |
| Operating Income | -118.67% | -87.22% | -31.38% | 49.06% | 59.09% |
| Income Before Tax | -9,169.79% | 18.06% | 51.95% | 118.05% | 100.62% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -9,169.79% | 18.06% | 51.95% | 118.05% | 100.62% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9,169.79% | 18.06% | 51.95% | 118.05% | 100.62% |
| EBIT | -118.67% | -87.22% | -31.38% | 49.06% | 59.09% |
| EBITDA | -119.31% | -87.64% | -31.55% | 49.12% | 59.19% |
| EPS Basic | -6,100.00% | 90.48% | 92.67% | 117.77% | 100.47% |
| Normalized Basic EPS | -31.03% | -23.98% | 5.30% | 51.16% | 58.77% |
| EPS Diluted | -459.46% | 72.69% | 76.67% | 102.37% | 93.40% |
| Normalized Diluted EPS | -27.91% | -18.88% | 9.09% | 53.75% | 59.24% |
| Average Basic Shares Outstanding | 90.80% | 55.51% | 23.90% | 4.11% | 1.51% |
| Average Diluted Shares Outstanding | 92.29% | 59.43% | 27.83% | 8.06% | 2.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |